Oncolytic adenovirus-expressed RNA interference of O6‑methylguanine DNA methyltransferase activity may enhance the antitumor effects of temozolomide

Chen,Xin-Jun; Zhang,Kai; Xin,Yong; Jiang,Guan

doi:10.3892/ol.2014.2442

Oncolytic adenovirus-expressed RNA interference of O6‑methylguanine DNA methyltransferase activity may enhance the antitumor effects of temozolomide

Authors:
- Xin-Jun Chen
- Kai Zhang
- Yong Xin
- Guan Jiang
View Affiliations

Affiliations: Clinical Laboratory, The Second Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China, Department of Radiotherapy, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China, Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China
Published online on: August 12, 2014 https://doi.org/10.3892/ol.2014.2442
Pages: 2201-2202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Temozolomide (TMZ) is an example of an alkylating agent, which are known to be effective anticancer drugs for the treatment of various solid tumors, including glioma and melanoma. TMZ acts predominantly through the mutagenic product O6‑methylguanine, a cytotoxic DNA lesion. The DNA repair enzyme, O6‑methylguanine DNA methyltransferase (MGMT), which functions in the resistance of cancers to TMZ, can repair this damage. RNA interference (RNAi) has been previously shown to be a potent tool for the knockdown of genes, and has potential for use in cancer treatment. Oncolytic adenoviruses not only have the ability to destroy cancer cells, but may also be possible vectors for the expression of therapeutic genes. We therefore hypothesized that the oncolytic virus‑mediated RNAi of MGMT activity may enhance the antitumor effect of TMZ and provide a promising method for cancer therapy.

View Figures

View References

1	O’Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 29A:940–942. 1993.
2	Bleehen NM, Newlands ES, Lee SM, et al: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 13:910–913. 1995.
3	Plummer ER, Middleton MR, Jones C, et al: Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O⁶-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res. 11:3402–3409. 2005.
4	Fan CH, Liu WL, Cao H, et al: O⁶-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis. 4:e8762013.
5	Jiang G, Xin Y, Zheng JN and Liu YQ: Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: a novel antitumor approach. Int J Cancer. 129:263–274. 2011.
6	Bischoff JR, Kirn DH, Williams A, et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:373–376. 1996.
7	Heise C, Hermiston T, Johnson L, et al: An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 6:1134–1139. 2000.
8	Rodriguez R, Schuur ER, Lim HY, et al: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57:2559–2563. 1997.
9	Garber K: China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 98:298–300. 2006.
10	Chu L, Gu J, Sun L, et al: Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Ther. 15:484–494. 2008.
11	Jiang G, Li LT, Xin Y, et al: Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT. Curr Med Chem. 19:3886–3892
12	Kuo CC, Liu JF and Chang JY: DNA repair enzyme, O⁶-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. J Pharmacol Exp Ther. 316:946–954. 2006.
13	Kato T, Natsume A, Toda H, et al: Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 17:1363–1371. 2010.
14	Zheng JN, Pei DS, Mao LJ, et al: Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther. 16:20–32. 2009.
15	Zheng JN, Pei DS, Sun FH, et al: Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene. Cancer Biol Ther. 8:84–91. 2009.